NASDAQ: SVRASavara Inc Stock
$5.15-0.08 (-1.53%)
Updated Mar 17, 2026
SVRA Price
$5.15
Fair Value Price
$0.01
Market Cap
$1.05B
52 Week Low
$1.89
52 Week High
$7.01
P/E
-9.72x
P/B
5.19x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$118.84M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.25
Operating Cash Flow
-$101M
Beta
0.83
Next Earnings
Mar 26, 2026
Ex-Dividend
N/A
Next Dividend
N/A
SVRA Overview
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SVRA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SVRA
Ranked#338 of 469
Ranked#338 of 469
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $15.49 | A | |
| $33.48 | A | |
| $181.37 | A |
Be the first to know about important SVRA news, forecast changes, insider trades & much more!
SVRA News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SVRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SVRA ($5.15) is overvalued by 34,892.23% relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SVRA ($5.15) is not significantly undervalued (34,892.23%) relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SVRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SVRA due diligence checks available for Premium users.
Valuation
SVRA fair value
Fair Value of SVRA stock based on Discounted Cash Flow (DCF)
Price
$5.15
Fair Value
$0.01
Overvalued by
34,892.23%
SVRA ($5.15) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SVRA ($5.15) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SVRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SVRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-9.72x
Industry
29.38x
Market
32.45x
SVRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.19x
Industry
4.76x
SVRA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SVRA's financial health
Profit margin
Revenue
$0.0
Net Income
-$32.2M
Profit Margin
0%
SVRA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$253.4M
Liabilities
$50.3M
Debt to equity
0.25
SVRA's short-term assets ($241.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SVRA's short-term assets ($241.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SVRA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SVRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$25.1M
Investing
-$93.6M
Financing
$135.6M
SVRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SVRA vs Biotech Stocks
Savara Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.